Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 4, 2006, Pages 564-569

  Cao, Hui ^a   Xu, Jia ^a   Liu, Hua ^a   Meng, Fang Bin ^a   Qiu, Jiang Feng ^a   Wu, Zhi Yong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cyclooxygenase; Hyperhemodynamics; Nitric oxide; Portal hypertension; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CARBON TETRACHLORIDE; CYCLOOXYGENASE 1; INDOMETACIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; RADIOACTIVE MICROSPHERE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; COLORIMETRY; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMODYNAMICS; LONG TERM CARE; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN OBSTRUCTION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; SPLANCHNIC BLOOD FLOW; SUPERIOR MESENTERIC ARTERY; THORACIC AORTA;

ANIMALS; CYCLOOXYGENASE 1; EPOPROSTENOL; GENE EXPRESSION; HYPERTENSION, PORTAL; INDOMETHACIN; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SPLANCHNIC CIRCULATION; TIME FACTORS;

EID: 33751243002     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bomzon A, Huang YT. Vascular smooth muscle cell signaling in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:255-272.
2. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005;25:1079-1090.
3. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002;17: 311-324.
4. Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination? Clin Sci 2004;107:425-434.
5. Huang HC, Wang SS, Chen YC, Lee FY, Chang FY, Lin HC, et al. Cyclooxygenase expression in splanchnic hyposensitivity to glypressin of bleeding portal hypertensive rats. Eur J Clin Invest 2003;33:505-512.
6. Cao H, Wu ZY, Zhou J, Jiao Z, Chen ZP, Kuang YL. Mechanism of overproduction of plasma prostacyclin in portal hypertensive rats. Chin Med J 1998;111:1064-1067.
7. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 1981;240:G371-G375.
8. Cao H, Wu ZY, Zhou J, Chen ZP, Kuang YL. Effects of nitric oxide inhibitor on prostacyclin biosynthesis in portal hypertensive rats. Chin Med J 1999;112:516-519.
9. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074-1081.
10. Theodorakis NG, Wang YN, Skill NJ, Metz MA, Cahill PA, Redmond EM, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003;124:1500-1508.
11. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006;44:209-216.
12. Moller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001;61:421-429.
13. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-293.
14. Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, et al. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology 1996;110:1529-1535.
15. Cao H, Wu ZY, Zhang XJ, Zhang H, Chen ZP, Kuang YL. The role of vasoactive substances in hyperhemodynamics after orthotopic liver transplantation in cirrhotic rats. Chin Med J 2003;116:505-509.
16. Fiorucci S, Antonelli E, Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig Liver Dis 2003;35:S61-69.
17. Le Q, Zhang X, Zhang J. Effects of sandostatin on gastric mucosal perfusion in rats with portal hypertensive gastropathy. Chin J Hepatol 2000;8:21-23.
18. Sun D, Huang A, Smith CJ, Stackpole CJ, Connetta JA, Shesely EG, et al. Enhanced Release of Prostaglandins Contributes to Flow-Induced, Arteriolar Dilation in eNOS Knockout Mice. Circ Res 1999;85:288-293.
19. Beverelli F, Bea ML, Puybasset L, Giudicelli JF, Berdeaux A. Chronic inhibition of NOS enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform. Fundam Clin Pharmacol 1997;11:252-259.
20. Wu ZY, Chen XS, Cao H, Chen XS. The effect of prostacyclin on formation and development of hyperdynamic circulatory state in portal hypertensive rats. Chin J Surg 2003;41:537-540.
21. Cao H, Xu J, Hua R, Meng FB, Qiu JF, Wu ZY. Expression of cyclooxygenase in hyperdynamic portal hypertensive rats. Hepatobiliary Pancreat Dis Int 2006;5:252-256.